Ono Pharmaceutical Co., Ltd.

Other

The University of Tokyo

Tokyo University of Science Foundation

Ono Pharmaceuticals Co., Ltd.

Tasuku Honjo

Medarex Inc.

Tokushima University

Ono Pharmaceuticalco.,ltd.

Honjo, Tasuku

Shiro Shibayama

Yoshikazu Takaoka

Masaya Kokubo

Nagahiro Minato

Hiroshi Ochiai

Yoshiko Iwai

Hiromu Habashita

Takao Yoshida

Kazuhiko Takeda

Masayoshi Matsuo

Hideaki Tada

Masakazu Miyamoto

Rena Nishizawa

Mark Throsby

Daikichi Fukushima

Pieter Fokko Van Loo

Motoyuki Tanaka

Rinse Klooster

Shin-ichi Hamano

Tomoya Tezuka

Cornelis Adriaan De Kruif

Kouji Matsushima

Yoshiro Ishiwata

Shoji Yokochi

Yoshimasa Tanaka

Satoshi Ueha

Tatsuya Tanihiro

Masamichi Imai

Takuya Shimbo

Shungo Deshimaru

Chang-Yu Chen

Koji Yoshida

Kousuke Tani

Hiroaki Mitsuya

Kensuke Kusumi

Akio Hayashi

Kazuya Hashimura

Takaki Komiya

Robertus Cornelis Roovers

Akira Ohhata

Toshihiko Nishiyama

Shinya Kusuda

Junya Ueda

Jun Murai

Takeo Maeda

Taku Okazaki

Daisuke Sugiura

Hiroshi Arima

Takuya Simbo

Kenji Maeda

Noriki Watanabe

Natsuko Tokuda

Miki Kasano

Tamon Hayashi

Nagahiro c/o Graduate School Of Biostudies Minato

Yoshimasa c/o Graduate School Of Biostudies Tanaka

An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.

Bispecific antibody

An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.

Immunosuppresive agent

A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.

Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.

HMGN partial peptide and cancer therapy using the same

A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.

Immunity enhancing agent for cancer by Allergin-1 antagonist

Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 &#x3bc;g/kg, and (c) without requiring administration for at least 3 months after the last administration.

Therapeutic agent for autoimmune diseases comprising PD-1 agonist

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Substance specific to human PD-1

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.

Immunopotentiative composition

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1 PD-L2 are useful for cancer or infection treatment.

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.

Growing community of inventors

Tsukuba, Japan

Shiro Shibayama